Genetic alterations at diagnosispredict outcome of AML patients age 60 or older undergoing allogeneic transplantation in first remission Meeting Abstract


Authors: Murdock, H. M.; Kim, H. T.; Hambley, B.; Vachhani, P.; Denlinger, N.; Gier, S. H.; Cho, C.; Perales, M. A.; Koreth, J.; Ho, V. T.; Soiffer, R. J.; McCurdy, S. R.; Carroll, M.; Vasu, S.; Wang, E. S.; Gondek, L. P.; Devine, S.; Alyea, E. P.; Gibson, C. J.; Lindsley, R. C.
Abstract Title: Genetic alterations at diagnosispredict outcome of AML patients age 60 or older undergoing allogeneic transplantation in first remission
Meeting Title: 61st Annual Meeting of the American Society of Hematology (ASH)
Abstract: DISCLOSURES: Perales: Bristol-Meyers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Incyte: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Nektar Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Omeros: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bellicum: Honoraria, Membership on an entity's Board of Directors or advisory committees; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees; NexImmune: Membership on an entity's Board of Directors or advisory committees; MolMed: Membership on an entity's Board of Directors or advisory committees; Merck: Consultancy, Honoraria; Medigene: Membership on an entity's Board of Directors or advisory committees; Servier: Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; Kyte/Gilead: Research Funding; Miltenyi: Research Funding. Koreth:Equillium: Consultancy; Amgen: Consultancy; Cugene: Consultancy. Ho:Jazz Pharmaceuticals: Consultancy. Soiffer:Mana therapeutic: Consultancy; Kiadis: Other: supervisory board; Juno, kiadis: Membership on an entity's Board of Directors or advisory committees, Other: DSMB; Gilead, Mana therapeutic, Cugene, Jazz: Consultancy; Jazz: Consultancy; Cugene: Consultancy. Carroll:Astellas Pharmaceuticals: Research Funding; Incyte: Research Funding; Janssen Pharmaceuticals: Consultancy. Vasu:Boehringer Ingelheim: Other: Travel support; Seattle Genetics: Other: Clinical trial support. Wang:Abbvie: Other: Advisory role; Kite: Other: Advisory role; Jazz: Other: Advisory role; Astellas: Other: Advisory role, Speakers Bureau; celyad: Other: Advisory role; Pfizer: Other: Advisory role, Speakers Bureau; Stemline: Other: Advisory role, Speakers Bureau; Daiichi: Other: Advisory role; Amgen: Other: Advisory role; Agios: Other: Advisory role. Devine:Kiadis Pharma: Other: Protocol development (via institution); Bristol Myers: Other: Grant for monitoring support & travel support; Magenta Therapeutics: Other: Travel support for advisory board; My employer (National Marrow Donor Program) has equity interest in Magenta. Lindsley:Jazz Pharmaceuticals: Research Funding; Takeda Pharmaceuticals: Consultancy; Medlmmune: Research Funding. © 2019 by The American Society of Hematology.
Keywords: adult; controlled study; human tissue; bone marrow; remission; funding; allotransplantation; travel; advisory committee; employer; human; article
Journal Title: Blood
Volume: 134
Issue: Suppl. 1
Meeting Dates: 2019 Dec 7-10
Meeting Location: Orlando, FL
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2019-11-13
Start Page: 48
Language: English
DOI: 10.1182/blood-2019-125967
PUBMED: 31724009
PROVIDER: scopus
DOI/URL:
Notes: Source: Scopus